In recent regulatory filings, it has been disclosed that Roger E. Susi, the CEO, President, and Chairman of IRADIMED CORP (NASDAQ:IRMD), has disposed of common stock valued at approximately $694,124. The sale occurred in two distinct phases on April 20 and April 21, 2026, with the share prices during these transactions fluctuating between $89.73 and $93.90.
Transaction Details
The total volume of the sale consisted of 7,500 shares of IRADIMED CORP common stock. These shares were held indirectly by the Phillip Susi 2008 Dynasty Trust. To ensure compliance and structured execution, the trades were carried out under a Rule 10b5-1 trading plan, which was originally adopted by Mr. Susi on November 5, 2025.
On April 20, the first phase of the sale involved 5,000 shares. These transactions were executed at weighted average prices of $93.14 and $93.90 per share. The specific price ranges for these trades were noted as being between $92.69 to $93.66 and $93.69 to $94.14, respectively.
The second phase of the disposal took place on April 21, involving an additional 2,500 shares. These were sold at weighted average prices ranging from $89.73 to $92.66 per share. The individual trades during this period saw price points between $89.18 and $92.89.
Post-Transaction Holdings
Following these recent sales, the Phillip Susi 2008 Dynasty Trust maintains an indirect holding of 2,202,500 shares of IRADIMED CORP common stock. In addition to this, Mr. Susi holds 162,950 shares indirectly through the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust. Regarding the latter, Mr. Susi disclaims beneficial ownership except for his specific pecuniary interest.
Market Context and Financial Performance
This insider activity occurs against a backdrop of significant stock movement; IRMD shares have seen a surge of 74% over the last year. However, current trading levels place the stock above its InvestingPro Fair Value, which categorizes it among the market's most overvalued assets at this time.
Despite the recent selling, the company recently reported strong financial outcomes for the fourth quarter of 2025. IRadimed Corporation exceeded analyst expectations during that period, with both revenue and earnings per share coming in higher than what was projected. Furthermore, Freedom Broker has initiated coverage on the company with a buy rating and a price target of $116.00, utilizing a five-year discounted cash flow model centered on free cash flow to the firm.
As investors look toward the next milestone, the company is scheduled to report its earnings in two days, on April 24.
Key Analysis Points
- Insider Liquidity and Structured Selling: The use of a Rule 10b5-1 plan indicates that these sales were part of a pre-determined strategy established months in advance (November 2025), rather than immediate reaction to current market conditions. This impacts the healthcare technology sector by providing clarity on executive divestment schedules.
- Valuation Divergence: There is a notable gap between recent stock performance (+74% annually) and current valuation metrics, as the stock is trading above its calculated Fair Value. This affects equity markets by highlighting potential volatility in overvalued mid-cap stocks.
- Positive Momentum Indicators: Despite the CEO's sale, the company maintains positive momentum from a fundamental perspective, evidenced by exceeding Q4 2025 expectations and receiving a favorable buy rating with a $116.00 target from Freedom Broker.
Risks and Uncertainties
- Valuation Risk: The fact that IRMD is currently positioned among the market's most overvalued stocks poses a risk to investors, particularly as it trades above its Fair Value. This impacts the broader medical device and technology sectors where high multiples can lead to corrections.
- Earnings Sensitivity: With earnings scheduled for April 24, the stock faces immediate uncertainty regarding how current market pricing will react to the upcoming financial disclosures.